Shanghai Yizhong and BAHEAL Pharmaceutical reached a strategic cooperation to accelerate the commercialization of innovative oncology drugs

Reporter Xie Lan trainee reporter Liu Zhao

On February 12, 2022, Shanghai Yizhong and BAHEAL Pharmaceutical signed a cooperation agreement in Qingdao to cooperate on the commercialization of Shanghai Yizhong's innovative tumor drug "Paclitaxel Polymer Micelle for Injection" (hereinafter referred to as "paclitaxel Micelle") zisheng, jointly promoting the accessibility of domestic tumor innovative drugs and benefiting many cancer patients in China.

Signing site

In the field of domestic innovative drugs with a hundred flowers, the commercialization environment is changing rapidly, and cooperation with professional third-party commercialization platforms to achieve win-win has become the mainstream choice of innovative pharmaceutical companies. At the signing ceremony, Zhou Jinsong, chairman of Shanghai Yizhong, said: "Shanghai Yizhong is committed to developing a new generation of innovative drugs to provide patients with safe, effective and affordable high-quality drugs to meet the treatment needs that need to be solved urgently. Paclitaxel micelle is our first product on the market, and in the stage of commercialization, we hope to cooperate with a professional third-party commercialization platform such as BAHEAL Pharmaceutical to jointly promote innovative drug products to enter the market and benefit more tumor patients. ”

As a professional health brand commercialization platform, BAHEAL Pharmaceutical relies on the three core capabilities of "brand operation with category insight, customer management of all-data platform, and mechanism to support long-term operation", and provides professional brand commercialization escort services for innovative drug enterprises, empowering innovative drug products to quickly enter application scenarios and breaking the dilemma of commercialization of innovative drugs after listing. At present, BAHEAL Pharmaceutical not only forms a rich brand matrix in the fields of OTC and prescription drugs such as Big Health and OTX, but also undertakes high-quality products such as Hierada and Trokai, Astellas' patented drug Betanley, which operate Roche Pharmaceutical.

Fu Gang, Chairman of BAHEAL Pharma, said: "As a third-party commercialization platform with brand operation as the core, BAHEAL Pharma has strict selection standards. The first is to eliminate pseudo-innovation with the heart and choose products that can truly optimize clinical application scenarios, the second is to rely on professional evaluation capabilities to evaluate the technical barriers of products to avoid falling into the dilemma of low-level duplication, and the third is to do a good job in element allocation with ecological collaboration, and select products that can truly complement and coordinate with BAHEAL resources for commercial operation. ”

"Paclitaxel micellar Zisheng is the third generation of paclitaxel, with significant efficacy and good safety, its distribution in tumor tissue is much higher than its distribution in the blood, is a revolutionary product." BAHEAL Pharmaceutical will do a good job in the allocation of elements according to the characteristics of its life cycle, formulate reasonable commercialization solutions, and help products release value. Fu Gang further said.

The cooperation between Shanghai Yizhong and BAHEAL Pharmaceutical will integrate the strong R&D strength of innovative drugs and excellent commercialization capabilities of both sides, and the two sides will join hands and are expected to bring new cooperation examples to the field of innovative drug commercialization.

(Edited by Tian Dong)